BR112014011333B1 - composto, composição farmacêutica e uso do composto de fórmula - Google Patents

composto, composição farmacêutica e uso do composto de fórmula Download PDF

Info

Publication number
BR112014011333B1
BR112014011333B1 BR112014011333A BR112014011333A BR112014011333B1 BR 112014011333 B1 BR112014011333 B1 BR 112014011333B1 BR 112014011333 A BR112014011333 A BR 112014011333A BR 112014011333 A BR112014011333 A BR 112014011333A BR 112014011333 B1 BR112014011333 B1 BR 112014011333B1
Authority
BR
Brazil
Prior art keywords
compound
glucocorticoid
pharmaceutical compositions
pregenen
triol
Prior art date
Application number
BR112014011333A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112014011333A2 (pt
Inventor
Nehme Alissar
L Edelman Jeffrey
C Malone Thomas
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47179019&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014011333(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of BR112014011333A2 publication Critical patent/BR112014011333A2/pt
Publication of BR112014011333B1 publication Critical patent/BR112014011333B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112014011333A 2011-11-11 2012-11-09 composto, composição farmacêutica e uso do composto de fórmula BR112014011333B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161558775P 2011-11-11 2011-11-11
PCT/US2012/064293 WO2013071009A1 (en) 2011-11-11 2012-11-09 4 - pregenen- 11ss - 17 - 21 -triol-3, 20 -dione derivatives for the treatment of ocular conditions

Publications (2)

Publication Number Publication Date
BR112014011333A2 BR112014011333A2 (pt) 2017-05-02
BR112014011333B1 true BR112014011333B1 (pt) 2020-04-28

Family

ID=47179019

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112014011333A BR112014011333B1 (pt) 2011-11-11 2012-11-09 composto, composição farmacêutica e uso do composto de fórmula
BR112014011341A BR112014011341A2 (pt) 2011-11-11 2012-11-09 composições farmacèuticas e métodos de uso de derivados de 4-pregenen-11beta-17-21-triol-3,20-diona

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR112014011341A BR112014011341A2 (pt) 2011-11-11 2012-11-09 composições farmacèuticas e métodos de uso de derivados de 4-pregenen-11beta-17-21-triol-3,20-diona

Country Status (24)

Country Link
US (7) US8865691B2 (cg-RX-API-DMAC7.html)
EP (2) EP2776040B1 (cg-RX-API-DMAC7.html)
JP (2) JP6158201B2 (cg-RX-API-DMAC7.html)
KR (2) KR102049615B1 (cg-RX-API-DMAC7.html)
CN (2) CN104185472B (cg-RX-API-DMAC7.html)
AR (1) AR088846A1 (cg-RX-API-DMAC7.html)
AU (3) AU2012335590B2 (cg-RX-API-DMAC7.html)
BR (2) BR112014011333B1 (cg-RX-API-DMAC7.html)
CA (3) CA2855290C (cg-RX-API-DMAC7.html)
CL (2) CL2014001243A1 (cg-RX-API-DMAC7.html)
CO (2) CO6970598A2 (cg-RX-API-DMAC7.html)
ES (1) ES2806603T3 (cg-RX-API-DMAC7.html)
HK (1) HK1200366A1 (cg-RX-API-DMAC7.html)
IL (2) IL232535B (cg-RX-API-DMAC7.html)
IN (2) IN2014CN03903A (cg-RX-API-DMAC7.html)
MX (3) MX365859B (cg-RX-API-DMAC7.html)
MY (2) MY172227A (cg-RX-API-DMAC7.html)
PH (2) PH12014501079B1 (cg-RX-API-DMAC7.html)
RU (2) RU2683775C2 (cg-RX-API-DMAC7.html)
SG (3) SG11201402225RA (cg-RX-API-DMAC7.html)
TW (1) TWI584809B (cg-RX-API-DMAC7.html)
UA (2) UA116622C2 (cg-RX-API-DMAC7.html)
WO (2) WO2013071010A1 (cg-RX-API-DMAC7.html)
ZA (2) ZA201403431B (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
UA116622C2 (uk) 2011-11-11 2018-04-25 Аллерган, Інк. Похідні 4-прегенен-11ss-17-21-тріол-3,20-діону для лікування хвороб очей
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
ES2750523T3 (es) 2012-12-18 2020-03-26 Almirall Sa Derivados de ciclohexil y quinuclidinil carbamato que tienen actividades de agonista beta2 adrenérgicos y antagonistas muscarínicos M3
TWI643853B (zh) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
TWI641373B (zh) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽
TW201517906A (zh) 2013-07-25 2015-05-16 Almirall Sa 含有ｍａｂａ化合物和皮質類固醇之組合
CN105814071A (zh) * 2013-12-13 2016-07-27 阿勒根公司 类固醇样化合物的多晶型物及其制备和使用方法
TW201617343A (zh) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物
KR20170120161A (ko) * 2015-03-05 2017-10-30 알러간, 인코포레이티드 안과용 약물 전달을 위한 자가-유화 약물 전달 시스템(sedds)
WO2018053321A1 (en) * 2016-09-16 2018-03-22 Kala Pharmaceuticals, Inc. Particles, compositions, and methods for ophthalmic and/or other applications
WO2019055028A1 (en) * 2017-09-15 2019-03-21 Kala Pharmaceuticals, Inc. PARTICLES, COMPOSITIONS AND METHODS FOR OPHTHALMIC APPLICATIONS AND / OR OTHER APPLICATIONS
CN116023425B (zh) * 2023-03-28 2023-06-20 南京师范大学 曲安西龙衍生物及其医药用途

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6605514A (cg-RX-API-DMAC7.html) * 1966-04-25 1967-10-26
IT1056711B (it) * 1967-04-01 1982-02-20 Vismara F Spa Derivati dell idrocortisone
US3484436A (en) 1967-09-07 1969-12-16 Syntex Corp Bicyclo(2.2.2)octane - 1 - -carboxylate esters of delta**4 - pregnene corticoid steroids
GB1227992A (cg-RX-API-DMAC7.html) * 1968-01-23 1971-04-15 Koninklijke Gist Spiritus
US3693032A (en) 1971-04-23 1972-09-19 Ibm Antisaturation technique for ttl circuits
US3984544A (en) * 1975-02-28 1976-10-05 Schering Corporation Retinoic acid esters of steroids of the pregnane series, their use in the treatment of acne and pharmaceutical formulations useful therefor
JPS52136157A (en) * 1976-04-14 1977-11-14 Taisho Pharmaceut Co Ltd Preparation of steroid 17-esters
JPS60994B2 (ja) * 1976-07-26 1985-01-11 大正製薬株式会社 プレグナン系化合物の１７α―エステル類の製造法
DE2735110A1 (de) * 1977-08-04 1979-02-15 Hoechst Ag Corticoid-17-alkylcarbonate und verfahren zu ihrer herstellung
US4221787A (en) * 1978-03-28 1980-09-09 Interx Research Corporation Esteramide prodrugs of anti-inflammatory corticosteroids
US4221778A (en) * 1979-01-08 1980-09-09 Pennwalt Corporation Prolonged release pharmaceutical preparations
DE4025342A1 (de) * 1990-08-10 1992-02-13 Hoechst Ag In 17-stellung substituierte corticoid-17-alkylcarbonate, verfahren zu deren herstellung und diese enthaltende arzneimittel
US6011023A (en) * 1997-08-27 2000-01-04 Alcon Laboratories, Inc. Angiostatic steroids
ATE241640T1 (de) * 1999-10-15 2003-06-15 Leo Pharm Prod Ltd Fusidinsäure-derivate
US6395721B1 (en) 2000-01-05 2002-05-28 Leonard Bloom Low potency unpreserved sterile topical corticosteroid compositions for dermatitis
NZ538932A (en) * 2002-08-29 2007-04-27 Boehringer Ingelheim Pharma 3-(sulfonamidoethyl)-indole derivatives for use as glucocorticoid mimetics in the treatment of inflammatory, allergic and proliferative disease
JP2005008596A (ja) * 2003-06-20 2005-01-13 Kobayashi Pharmaceut Co Ltd 眼科用組成物
DK1755616T3 (da) * 2004-04-08 2013-11-25 Eye Co Pty Ltd Behandling af ekssudativ retinopati med mineralkortikoider
AU2005271700B2 (en) * 2004-07-12 2010-11-11 Allergan, Inc. Opthalmic compositions and methods for treating ophthalmic conditions
US7687484B2 (en) * 2006-05-25 2010-03-30 Bodor Nicholas S Transporter enhanced corticosteroid activity
US7691811B2 (en) * 2006-05-25 2010-04-06 Bodor Nicholas S Transporter-enhanced corticosteroid activity and methods and compositions for treating dry eye
EP1864668B1 (en) 2006-06-01 2012-11-21 Novagali Pharma S.A. Use of prodrugs for ocular intravitreous administration
ES2493641T3 (es) * 2007-06-28 2014-09-12 Cydex Pharmaceuticals, Inc. Administración nasal de soluciones acuosas de corticosteroides
JP2009053880A (ja) 2007-08-27 2009-03-12 Sony Broadband Solution Corp 情報処理装置、ならびにｃｐｕユニット
CN101970452A (zh) * 2007-12-21 2011-02-09 先灵公司 C20-c21取代的糖皮质激素受体激动剂
MX2010013562A (es) * 2008-06-26 2011-02-15 Anterios Inc Aplicacion dermica.
UA116622C2 (uk) 2011-11-11 2018-04-25 Аллерган, Інк. Похідні 4-прегенен-11ss-17-21-тріол-3,20-діону для лікування хвороб очей

Also Published As

Publication number Publication date
US10188667B2 (en) 2019-01-29
JP2014533274A (ja) 2014-12-11
JP2014533275A (ja) 2014-12-11
RU2014123471A (ru) 2015-12-20
MX2019006877A (es) 2019-08-22
MX2014005678A (es) 2014-12-10
US9433631B2 (en) 2016-09-06
AU2012335589B2 (en) 2017-08-31
CN104203247A (zh) 2014-12-10
HK1200366A1 (en) 2015-08-07
US20150057258A1 (en) 2015-02-26
TWI584809B (zh) 2017-06-01
UA116622C2 (uk) 2018-04-25
NZ624920A (en) 2017-06-30
MY172227A (en) 2019-11-18
PH12014501078B1 (en) 2014-07-28
EP2776040B1 (en) 2020-04-22
JP6158201B2 (ja) 2017-07-05
AR088846A1 (es) 2014-07-10
US20190365786A1 (en) 2019-12-05
IL232534A0 (en) 2014-06-30
PH12014501078A1 (en) 2014-07-28
CA2855290A1 (en) 2013-05-16
MX363669B (es) 2019-03-29
RU2683775C2 (ru) 2019-04-02
ZA201403430B (en) 2016-05-25
CL2014001243A1 (es) 2014-11-28
AU2012335590B2 (en) 2017-10-19
KR20140095548A (ko) 2014-08-01
WO2013071009A1 (en) 2013-05-16
US20170182062A1 (en) 2017-06-29
CA2855290C (en) 2017-02-28
CA2855929C (en) 2018-03-27
US8865691B2 (en) 2014-10-21
AU2018200436B2 (en) 2019-10-24
CN104203247B (zh) 2017-06-06
EP2776040A1 (en) 2014-09-17
CA2991883C (en) 2020-03-10
CN104185472A (zh) 2014-12-03
CA2855929A1 (en) 2013-05-16
HK1200367A1 (en) 2015-08-07
WO2013071010A1 (en) 2013-05-16
US8906892B2 (en) 2014-12-09
UA111867C2 (uk) 2016-06-24
CL2014001244A1 (es) 2014-11-14
CN104185472B (zh) 2017-06-13
IN2014CN03903A (cg-RX-API-DMAC7.html) 2015-10-16
MY182222A (en) 2021-01-18
BR112014011333A2 (pt) 2017-05-02
KR102049615B1 (ko) 2019-11-28
AU2012335590A1 (en) 2014-05-29
EP2776041A1 (en) 2014-09-17
US20130123223A1 (en) 2013-05-16
JP6216719B2 (ja) 2017-10-18
IL232535A0 (en) 2014-06-30
US20150005519A1 (en) 2015-01-01
SG11201402247PA (en) 2014-06-27
SG10201603766PA (en) 2016-07-28
TW201325596A (zh) 2013-07-01
KR20140095549A (ko) 2014-08-01
RU2014123472A (ru) 2015-12-20
MX2014005679A (es) 2014-12-10
US20130123226A1 (en) 2013-05-16
PH12014501079A1 (en) 2014-07-28
CO6970609A2 (es) 2014-06-13
AU2012335589A1 (en) 2014-05-29
CA2991883A1 (en) 2013-05-16
US10493082B2 (en) 2019-12-03
BR112014011341A2 (pt) 2017-05-02
IN2014CN03919A (cg-RX-API-DMAC7.html) 2015-09-04
AU2018200436A1 (en) 2018-02-08
NZ624919A (en) 2016-10-28
RU2688159C2 (ru) 2019-05-20
US9717743B2 (en) 2017-08-01
PH12014501079B1 (en) 2014-07-28
IL232535B (en) 2019-09-26
MX365859B (es) 2019-06-18
ES2806603T3 (es) 2021-02-18
US20180147217A1 (en) 2018-05-31
CO6970598A2 (es) 2014-06-13
SG11201402225RA (en) 2014-06-27
ZA201403431B (en) 2016-05-25

Similar Documents

Publication Publication Date Title
BR112014011333A2 (pt) derivados de pregenen-11ss-17-21-triol-3,20-diona para o tratamento de condições oculares
BR112014031375A2 (pt) moduladores da série de reação complementar e usos dos mesmos
BR112013000254A2 (pt) derivados heterocíclicos 1-fenil-substituídos e seu uso como moduladores do receptor de prostaglandina d2
BR112015007818A2 (pt) composto, composição farmacêutica, e, uso de um composto e de uma composição farmacêutica
BR112013026807A2 (pt) derivados de metil amina bicíclicos substituídos como moduladores dos receptores de esfinfgosina-1 fosfato
EA201400567A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ЦИКЛОГЕКСИЛАМИНА, ОБЛАДАЮЩИЕ АГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К β2 АДРЕНЕРГИЧЕСКОМУ РЕЦЕПТОРУ И АНТАГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К МУСКАРИНОВОМУ РЕЦЕПТОРУ М3
BR112014001908A2 (pt) derivados aza heterocíclicos substituídos
BR112012012261A2 (pt) compostos como moduladores de receptor com utilidade terapêutica
EA201390969A1 (ru) Модуляторы глюкагонового рецептора
EA201190234A1 (ru) Новые амидные производные стероидных соединений [3,2-c]пиразолов с глюкокортикоидной активностью
PH12019501724A1 (en) Estrogen receptor modulators
PH12012501863A1 (en) 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
MX2011012669A (es) Nuevos agonistas del receptor de glucocorticoides.
BR112014012459A2 (pt) 2h-indazóis como antagonistas do receptor de ep2
BR112017012588B8 (pt) Compostos heteroaril-heteroarila bicíclicos de ácido benzoico, seus usos, composições farmacêuticas, métodos de preparação destas e métodos para provocar ou promover o desenvolvimento de neuritos, o crescimento de neuritos e/ou a regeneração de neuritos e para ativar o receptor beta do ácido retinoico
BR112014001714A2 (pt) derivados de carboxamida e ureia aromáticos bicíclicos substituídos como ligantes de receptor vaniloide
BR112013012719A2 (pt) "compostos como moduladores de receptor com utilidade terapêutica".
BR112014011262A2 (pt) carboxamida com base em pirazolila substituída e derivados de ureia que portam uma porção de fenila substituída com um grupo contendo o como ligantes de receptor vaniloide
BR112015006243A2 (pt) agentes antibacterianos de fenicol
BR112014006675A2 (pt) derivados de metanossulfonamida substituídos como ligantes de receptor vaniloide
HK1211916A1 (en) Arylalkylamine compounds as calcium sensing receptor modulators
BR112014006788A2 (pt) derivados de metanossulfonamida substituídos com arila ou n-heteroarila como ligantes de receptor vaniloide
BR112014000288A2 (pt) moduladores do receptor de glucagon de quinolinila
BR112014011108A2 (pt) derivados de carboxamida e ureia à base de pirazolila substituída portando uma porção fenila substituída com um grupo contendo so2 como ligantes do receptor de vaniloides
BR112014006927A2 (pt) derivados de metanossulfonamida substituídos com amina como ligantes de receptor vaniloide

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/11/2012, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 9A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2643 DE 31-08-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.